SynthesisFrontiers in psychiatry2025
Discovery of biological markers for schizophrenia based on metabolomics: a systematic review.
Synthesis in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adjunctive transcranial direct current stimulation for cognitive improvement in schizophrenia: insights from a systematic review and exploratory meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Untargeted metabolomics reveals plasma metabolic dysregulation in schizophrenia.BMC psychiatry · 2026Article
- Alterations in lipid, redox, and energy metabolism in recent onset psychosis: a metabolomics study in non-smoking individuals and matched controls.Redox biology · 2026Article
- The kynurenine pathway in depression and schizophrenia: convergent signals, divergent states, and clinical signatures.EXCLI journal · 2026Review
- Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases.Current neuropharmacology · 2026Review
- Metabolomics biomarkers for precision psychiatry.Frontiers in psychiatry · 2026Review
- Metabolic Plasticity in Schizophrenia: Clinical Rehabilitation Meets LC-MS Metabolomics and Neurofeedback.International journal of molecular sciences · 2025Article
- Neuronal subtype-specific metabolic changes in neurodegenerative and neuropsychiatric diseases predicted via a systems biology-based approach.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and methods: To discover biomarkers for schizophrenia (SCZ) at the metabolomics level, we registered this systematic review (CRD42024572133 (https://www.crd.york.ac.uk/PROSPERO/home)) including 56 qualified articles, and we identified the characteristics of metabolites, metabolite combinations, and metabolic pathways associated with SCZ. Results: Our findings showed that decreased arachidonic acid, arginine, and aspartate levels, and the increased levels of glucose 6-phosphate and glycylglycine were associated with the onset of SCZ. Metabolites such as carnitine and methionine sulfoxide not only helped to identify SCZ in Miao patients, but also were different between Miao patients and Han patients. The decrease in benzoic acid and betaine and the increase in creatine were the notable metabolic characteristics of first-episode schizophrenia (FESCZ). The metabolite combination formed by metabolites such as methylamine, dimethylamine and other metabolites had the best diagnostic effect. Arginine and proline metabolism and arginine biosynthesis had a clear advantage in identifying SCZ and acute SCZ. Butanoate metabolism played an important role in identifying SCZ, toxoplasma infection and SCZ comorbidity. Biosynthesis of unsaturated fatty acids was also significantly enriched in the diagnosis and treatment of SCZ. Discussion: This study summarizes the current progress in clinical metabolomic research related to SCZ, deepens understanding of the pathogenesis of SCZ, and lays a foundation for subsequent research on SCZ-related metabolites. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/home, identifier CRD42024572133.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.